Spero Therapeutics, Inc. (SPRO)
NASDAQ: SPRO · Real-Time Price · USD
1.165
-0.035 (-2.92%)
Nov 21, 2024, 1:01 PM EST - Market open

Company Description

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States.

The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.

It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite.

Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Spero Therapeutics, Inc.
Spero Therapeutics logo
Country United States
Founded 2013
IPO Date Nov 2, 2017
Industry Biotechnology
Sector Healthcare
Employees 46
CEO Satyavrat Shukla

Contact Details

Address:
675 Massachusetts Avenue, 14th Floor
Cambridge, Massachusetts 02139
United States
Phone 857 242 1600
Website sperotherapeutics.com

Stock Details

Ticker Symbol SPRO
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001701108
CUSIP Number 84833T103
ISIN Number US84833T1034
SIC Code 2834

Key Executives

Name Position
Satyavrat Shukla C.F.A. President, Chief Executive Officer and Director
Dr. Ankit Mahadevia M.D., MBA Co-Founder and Chairman of the Board
Timothy Keutzer Chief Operating Officer
Esther P. Rajavelu Chief Financial Officer, Chief Business Officer and Treasurer
James P. Brady Chief Human Resource Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Oct 29, 2024 8-K Current Report
Sep 10, 2024 8-K Current Report
Aug 5, 2024 S-8 Securities to be offered to employees in employee benefit plans
Aug 5, 2024 10-Q Quarterly Report
Aug 5, 2024 8-K Current Report
Jun 3, 2024 8-K Current Report
May 15, 2024 8-K Current Report